BOARD OF DIRECTORS

Timothy Warbington

Mr. Warbington has over 25 years of executive level management experience.  Mr. Warbington has an Accounting degree from Arizona State University.  For 15 years, he owned a national agricultural (produce) and finance company with annual revenues of $8,000,000 to $12,000,000.  Prior to that, he served as Chief Operating Officer of the U.S. subsidiary of a British firm engaged in the international food trade.  For eight years, Mr. Warbington has invested in the biotechnology industry and has provided strategic and tactical advice as a consultant to a publically traded bio-tech firm.  In connection with this experience, he has built a network of scientists, physicians and executives to participate as executive officers and directors of CMH.

Amit Patel MS MD

Dr. Patel currently holds the following positions at the University of Utah; Associate Professor, Department of Surgery, Division of Cardiothoracic Surgery and Director Clinical Regenerative Medicine and Tissue Engineering. Dr. Patel has an MD from Case Western Reserve University. Dr. Patel is an accomplished inventor and has contributed to the formulation of the Company’s Bionutraceutical® products.

Thomas Ichim PhD

Dr. Ichim has 20 years experience in the biotechnology industry, having served as the Vice President of Cellular Therapies, Intrexon, Inc. Dr. Ichim is an accomplished inventor and was the President and Chief Scientific Officer at Medistem, Inc., a recently acquired publicly traded company. Dr. Ichim has a PhD in Immunology from University of Sciences Arts and Technology, Olveston Monserrat, a MSc in Microbiology and Immunology from University of Western Ontario, London, Ontario, Canada and a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada. Dr. Ichim has written over 100 peer reviewed publications and has founded and operated successful biotech companies in the past.

 


 

MANAGEMENT

Timothy Warbington

(President – CEO) Mr. Warbington has over 25 years of executive level management experience. Mr. Warbington has an Accounting degree from Arizona State University. For 15 years, he owned a national agricultural (produce) and finance company with annual revenues of $8,000,000 to $12,000,000. Prior to that, he served as Chief Operating Officer of the U.S. subsidiary of a British firm engaged in the international food trade. For eight years, Mr. Warbington has invested in the biotechnology industry and has provided strategic and tactical advice as a consultant to a publically traded bio-tech firm. In connection with this experience, he has built a network of scientists, physicians and executives to participate as executive officers and directors of CMH.

Thomas Ichim PhD

(Sr. Vice President CMH – President – CEO Biotechnology Division) Dr. Ichim has 20 years experience in the biotechnology industry,   having served as the Vice President of Cellular Therapies, Intrexon, Inc.  Dr. Ichim is an accomplished inventor and was the President and Chief Scientific Officer at Medistem, Inc., a recently acquired publicly traded company.  Dr. Ichim has a PhD in Immunology from University of Sciences Arts and Technology, Olveston Monserrat, a MSc in Microbiology and Immunology from University of Western Ontario, London, Ontario, Canada and a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada. Dr. Ichim has written over 100 peer reviewed publications and has founded and operated successful biotech companies in the past.

Michael Finger MBA

(Treasurer and Chief Financial Officer) – Mr. Finger has a Bachelor of Arts in Biology from Boston University and a Masters of Business Administration, Finance from Columbia University. Mr. Finger has extensive experience in banking and finance. He is known for assisting with the acquisition of on-going businesses and the establishment of new management and operational systems to position businesses for sale. He is currently the CFO of Hyland Bay, a national sales training firm.

Thomas Rouse, Esq.

(Secretary) – Mr. Rouse is the Company’s corporate counsel.

Annette Marleau Phd

(Vice President and Chief Scientific Officer)- Prior to joining CMH, Dr. Marleau was the Director of Tumor Immunology at Aethlon Medical Inc. Dr. Marleau has a PhD in Immunology from the University of Western Ontario as well as a MS in Reproductive Immunology from Ontario Veterinary Collateral, University of Guelph, Canada and a BS in Biology from the University of Waterloo, Canada.

Donald Dickerson MBA

(Vice President and Chief Operating Officer) – Mr. Dickerson has a Masters of Business Administration, Finance from the University of Southern California. Mr. Dickerson has worked in a number of management and accounting positions and has experience with companies in the technology, manufacturing and health sciences area. Mr. Dickerson’s experience includes leadership positions at BioRasi, Dell, Boeing Capital and Medistem, Inc.

 


 

SCIENTIFIC ADVISORY BOARD

CMH maintains a Scientific Advisory Board to provide the Company with the benefit of the professional observations, questions, advice and recommendations of experienced scientific professionals.

Masato Mitsuhashi MD PhD

Dr. Mitsuhashi is currently the Chief Technology Officer of Nanosomix. Dr. Mitsuhashi’s experience also includes Chief Scientific Officer at Hitachi Chemical Research Corporation.

Eric Duckers MD PhD

Dr. Duckers is currently Assistant Professor, Erasmus Medical Center, Head, Molecular Cardiology Laboratory, Erasmus Medical Center and Interventional Cardiologist, Erasmus Medical Center, Rotterdam, Netherlands.

Timothy Henry MD

Dr. Henry is currently the Director of Cardiology, Cedars-Sinai Heart Institute. Dr. Henry’s experience also includes Director of Research at Minneapolis Heart Institute Foundation.

Warren Sherman MD

Dr. Sherman is currently the Chief Medical Officer at Cardio 3 and was formerly Director of Cardiac Cell-Based Endovascular Therapies, Columbia University Medical Center and New York Presbyterian Hospital.

 


 

Featured Products

View our Bestsellers

Recent Blog entries

View Blog